Determination of chemically reduced pyrrolobenzodiazepine SJG‐136 in human plasma by HPLC‐MS/MS: application to an anticancer phase I dose escalation study

Abstract

SJG-136 1,1'-[[(propane-1,3-diyl)dioxy]bis[(11aS)-7-methoxy-2-methylidene-1,2,3,11a-tetrahydro-5H-pyr- rolo[2,1-c][1,4]benzodiazepin-5-one]] (NSC 694501), is a bifunctional pyrrolobenzodiazepine (PBD) dimer that forms selective, irreversible, interstrand DNA cross-links via exocyclic N2 atoms of two guanine bases, with a preference for 5'PuGATCPy binding sites. SJG-136 is highly cytotoxic in human tumor cells in vitro and in human tumor xenograft models in vivo at subnanomolar concentrations and is currently in anticancer phase I clinical trials in the United Kingdom and United States. To support correlative pharmacokinetics studies, a highly sensitive HPLC-MS/MS assay was developed and validated for the reliable quantitation of SJG-136 in human plasma, using the structurally similar PBD dimer DSB-120 as an internal standard. Chemical reduction of SJG-136 to its corresponding amine (SJG-136-H(4), [M + H](+)m/z 561) improved HPLC peak resolution and sensitivity by minimizing complications that arose from the reactivity of the labile imine moieties. Plasma samples were processed by protein precipitation and centrifugal membrane dialysis; components were separated by HPLC using an Agilent Rapid Resolution HT 1.8 mm (2.1 mm x 50 mm) analytical column. The total analysis time from injection to injection was 11 min. Electrospray MS/MS detection of SJG-136-H(4) was based on the selected reaction monitoring (SRM) transition [M + H](+)m/z 561 --> 301. The analytical response ratio was linearly proportional to the plasma concentration of SJG-136 over the nominal concentration range of 25 pg/ml to 250 ng/ml, with a coefficient of determination of r > or = 0.999. The intrarun absolute %RE was < or =19.6, 14.2, and 14.0% at 0.056, 2.83, and 56.3 ng/ml, respectively. The corresponding %RSD was < or =14.9%, 9.01, and 4.59%. The interday %RSD was < or =2.72, 3.46, and 5.20%. The lower and upper limits of quantitation were 0.056 and 56 ng/ml, respectively; recovery of SJG-136 from plasma was > or = 62% across the validated concentration range. The sensitivity of the validated assay was sufficient to detect SJG-136 in human subjects for up to 6 h after intravenous administration of 6 microg/m(2), the starting dose of an NCI-sponsored dose escalation study.

The association of the kynurenine pathway of tryptophan metabolism with acute brain dysfunction during critical illness*

“…Plasma tryptophan concentrations were measured using high-performance liquid chromatography (58), and plasma kynurenine was measured with high-performance liquid chromatography plus tandem mass spectrometry using a variation of a previously described method (59). The kynurenine and kynurenine/tryptophan ratio were both used as indicators of kynurenine pathway activity, because tryptophan metabolism to kynurenine is the rate-limiting step in the kynurenine pathway (60).…”

Phase I Pharmacokinetic and Pharmacodynamic Study of SJG-136, a Novel DNA Sequence Selective Minor Groove Cross-linking Agent, in Advanced Solid Tumors

“…SJG-136 plasma concentration levels were determined using liquid chromatography-tandem mass spectrometry analysis 10. Noncompartmental PK analyses were performed using the WinNonlin software package, version 4.1 (Pharsight Corp., Palo Alto, CA).…”

A phase I trial of SJG-136 (NSC#694501) in advanced solid tumors

“…Determination of SJG-136 plasma concentration levels was performed using a recently validated liquid chromatography mass spectrometry analytical method [8]. Non compartmental PK parameters were obtained using the WinNonlin software package, version 4.1 (Pharsight Corp., Palo Alto, CA).…”